Flowers Kirsten 的 Form 4/A 修正申報
修正Comera Life Sciences Holdings, Inc.CMRA,2023/2/14 申報
- 申報編號
- 0001062993-23-003492
- 申報時間
- 2023/2/14 17:27 ET
- 交易日
- 2023/1/4
- 申報延遲
- 41 天
- 10b5-1 計畫
- 表單沒有這欄(2023 年以前)
- 原始申報日
- 2023/1/6
這份申報列了 1 筆非衍生性交易、1 筆衍生性交易。公開市場買進合計 $1.66 萬。交易後 41 天申報。
這份修正申報取代了 0001062993-23-000607(2023/1/6 申報)。
申報人
一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Flowers KirstenCIK 0001797209 | 董事 |
非衍生性證券(表 I)
普通股等股票的取得與處分,每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2023/1/4 | Common Stock | P買進取得 | +13,513 | $1.23F2 | +$16,620.99 | 22,199 | 直接 |
衍生性證券(表 II)
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數;單價與金額是衍生證券本身的價格,交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2023/1/4 | Common Stock | P買進取得 | +27,026 | $0.25 | +$3,378.25 | 13,513 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。
- F1
This Form 4/A is being filed to (i) correct a typographical error in the transaction code disclosed in Column 3 in Table I and Column 4 in Table II in the original Form 4, filed on January 6, 2023, from "A" to "P" and (ii) correct a typographical error in the power-of-attorney of the reporting person.
- F2
The reporting person entered into a Securities Purchase Agreement with the Issuer on January 2, 2023, pursuant to which, on January 4, 2023, the reporting person acquired an aggregate of 13,513 units (the "Units") for a purchase price of $1.48 per Unit. Each Unit consists of one share of common stock, par value $0.0001 per share (the "Common Stock"), and one warrant (the "Warrants") to purchase two shares of Common Stock (the "Warrant Shares") at an exercise price of $1.23 per share. Each Warrant is immediately exercisable and expires five years from the date of issuance. The purchase price for each Unit includes $0.125 for each Warrant Share, or $0.25 per Warrant, in accordance with Nasdaq rules.
表 I 有 1 筆交易的價格引用這則附註。
- F3
The exercisability of the Warrants is subject to a 4.99% beneficial ownership limitation.
備註
Exhibit 24 Power of Attorney filed herewith.